Is Tonix Pharmaceuticals Holding Corp (TNXP) a Stock to Watch After Gaining 2.04% This Week?

Overall market sentiment has been high on Tonix Pharmaceuticals Holding Corp (TNXP) stock lately. TNXP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Tonix Pharmaceuticals Holding Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TNXP!

See Full TNXP Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With TNXP Stock Today?

Tonix Pharmaceuticals Holding Corp (TNXP) stock is down -2.91% while the S&P 500 has risen 1.66% as of 3:30 PM on Friday, Sep 9. TNXP is lower by -$0.03 from the previous closing price of $1.03 on volume of 3,416,451 shares. Over the past year the S&P 500 has fallen -9.78% while TNXP is lower by -95.33%. TNXP lost -$6.55 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Tonix Pharmaceuticals Holding Corp click here.

More About Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. Click Here to get the full Stock Report for Tonix Pharmaceuticals Holding Corp stock.